A randomised controlled trial of insulin lispro given before or after meals in pregnant women with type 1 diabetes--the effect on glycaemic excursion.
In order to study the glucose excursion associated with pre- and postprandial administration a randomised controlled trial with patients randomised to receive insulin lispro (IL) immediately before or after a standardised meal was performed. Pregnant women with diabetes who were treated with IL as part of a basal bolus regime were asked to bring their own usual lunch and administer their own IL. Maternal glycaemia was monitored preprandially and then at 15-minute intervals for 3 hours following the first bite of lunch. Glucose excursions were calculated by subtracting the preprandial glucose level from the subsequent values at each time point. Each woman was invited to attend on four occasions. On two random occasions she was asked to administer her IL after completing her meal and on two occasions IL was administered immediately before her meal. Nine women completed a total of 27 meals (14 preprandial IL and 13 postprandial IL). There was no significant difference between the mean (SD) fasting values between the two groups, before 5.8 (2.8) and after 5.7 (2.0) mmol/l. At each time-point there was no significant difference between the mean blood glucose excursion in the two groups. No patient suffered a hypoglycaemic attack and there was no evidence of fetal compromise. In the two groups there was a marked similarity in the glycemic excursion following a standard meal, whether or not IL was given before or after eating. Postprandial administration of IL may increase the flexibility of IL usage in pregnant women with diabetes.
Carr
K J E
KJ
Department of Obstetrics and Gynaecology, Hull Royal Infirmary, Hull, UK.
Idama
T O
TO
Masson
E A
EA
Ellis
K
K
Lindow
S W
SW
D000328:Adult; D001786:Blood Glucose; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004435:Eating; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007279:Injections, Subcutaneous; D007328:Insulin / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D061268:Insulin Lispro; D019518:Postprandial Period; D011247:Pregnancy; D011254:Pregnancy in Diabetics / Q000097:blood / Q000188:drug therapy*; D016896:Treatment Outcome
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D061268:Insulin Lispro